Form 4: Seres Therapeutics Executive Matthew Henn Reports Stock Sales to Cover Taxes

Matthew Henn, Chief Scientific Officer and EVP of Seres Therapeutics, reports the sale of common stock to cover taxes related to vesting restricted stock units.

Summary

• On February 15, 2025, Matthew R. Henn acquired 2,813 shares of common stock through the vesting of restricted stock units.
• On the same day, he acquired another 7,813 shares of common stock through the vesting of additional restricted stock units.
• On February 18, 2025, Henn sold 3,953 shares of common stock at a weighted average price of $0.8104 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 13, 2023, to cover tax obligations associated with the vesting of restricted stock units.
• Following these transactions, Henn directly owns 84,443 shares of Seres Therapeutics common stock.
• Henn also holds 22,500 restricted stock units and 23,437 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive under a pre-existing plan. It doesn't inherently indicate positive or negative news about the company.

Industry Context

This filing is a routine disclosure of insider transactions and is a common occurrence for executives who receive stock-based compensation. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates

Keywords

Seres Therapeutics, MCRB, Matthew Henn, Form 4, Stock Sale, Restricted Stock Units, Rule 10b5-1, Insider Trading